Yosra M. Aljawai, MD, MS
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2018 | St. George University School of Medicine, St. George, West Indies, GD, Medical Degree |
| 2009 | Rush University, Chicago, Illinois, US, M.S. in Immunology and Microbiology |
Postgraduate Training
| 2021-2023 | Science of Clinical Investigation Award Program, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland |
| 2020-2023 | Clinical Fellowship, Hematology, Johns Hopkins University SOM, Baltimore, Maryland |
| 2018-2020 | Physician Scientist Residency, Internal Medicine, Icahn SOM at The Mount Sinai Hospital, New York, New York |
Board Certifications
| 2022 | The American Board of Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
SCT&CT Representative, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - 2027
Interviewer for Hematology Oncology Fellowship Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, 2021 - 2023
Social Chair, Class of 2023, Department of Hematology and Medical Oncology Fellowship Program, Johns Hopkins University, Baltimore, Maryland, 2020 - 2023
House Staff Representative, Class of 2020, Department of Internal Medicine Residency, Icahn SOM at The Mount Sinai Hospital, New York, NY, 2018 - 2020
Other Appointments/Responsibilities
Nocturnist Admitting Physician, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, 2021 - 2023
COVID19 Call Center Support-Triage Physician, Johns Hopkins Hospital, Baltimore, MD, 2020 - 2021
USMLE tutor, STEP 2 United States Medical Licensing Examination, TutorZ, LLC, Baltimore, MD, 2019 - 2020
Clinical Research Coordinator & Laboratory Researcher, Mentor: Irene Ghobrial, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 2011 - 2014
Honors & Awards
| 2018 | Cum Laude, St. George University SOM |
| 2018 | Research Designation Award, St. George University SOM |
| 2017 - 2020 | Honor Member, Gold Humanism Honor Society |
| 2016 | Pathology Best Lab Group of 2016 Award, St. George University SOM |
| 2014 - 2018 | The Legacy of Excellence Scholarship, St. George University SOM |
| 2013 | Abstract Achievement Award, American Society of Hematology |
| 2007 - 2009 | Full scholarship, The Ministry of Higher Education, Master's Degree |
| 2006 - 2007 | Full scholarship, The Ministry of Higher Education, English as a Second Language Certificate |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Pasvolsky, O, Abid, MB, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Jatoi, A, Khan, HN, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Siddiqui, U, Aljawai, YM, Kebriaei, P, Lee, HC, Patel, K, Gaballa, MM, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. British Journal of Haematology 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
- Mehta, RS, Choe, H, Saultz, J, Gong, Z, Sharma, P, Al-Juhaishi, T, Petitto, GS, Lazaryan, A, Singh, AK, Xue, E, Dimitrova, D, Hyder, M, McCurdy, SR, Im, A, Huber, BD, Aljawai, YM, Kanakry, JA, Milano, F, Kanakry, CG. Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. American journal of hematology 100(6):987-997, 2025. e-Pub 2025. PMID: 40071498.
- Pasvolsky, O, Marcoux, C, Wang, Z, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Syed, N, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Ye, JC, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
- Marcoux, C, Pasvolsky, O, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Ahmed, A, Aljawai, YM, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplantation and Cellular Therapy 31(1):12.e1-12.e10, 2025. e-Pub 2025. PMID: 39448031.
- Pasvolsky, O, Ghanem, S, Milton, D, Rauf, M, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Khan, HN, Kebriaei, P, Lee, HC, Patel, K, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38199987.
- Pasvolsky, O, Wang, Z, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Kebriaei, P, Aljawai, YM, Khan, HN, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38760362.
- Pasvolsky, O, Marcoux, C, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Lee, J, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Kebriaei, P, Becnel, M, Lee, HC, Patel, K, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39482325.
- Aljawai YM, Tsai HL, Varadhan R, Jones RJ, Imus PH. Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis. Br J Haematol 205(4):1469-1476, 2024. e-Pub 2024. PMID: 39099174.
- Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
- Imus PH, Pasca S, Tsai HL, Aljawai Y, Cooke KR, Walston JD, Gocke CD, Varadhan R, Jones RJ, Gondek LP. Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Advances 8(14):3849-3858, 2024. e-Pub 2024. PMID: 38640196.
- Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M. Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One 13(10):e0204589, 2018. e-Pub 2018. PMID: 30286096.
- Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep 19(1):218-224, 2017. e-Pub 2017. PMID: 28380360.
- Roccaro AM, Sacco A, Shi J, Chiarini M, Perilla-Glen A, Manier S, Glavey S, Aljawai Y, Mishima Y, Kawano Y, Moschetta M, Correll M, Improgo MR, Brown JR, Imberti L, Rossi G, Castillo JJ, Treon SP, Freedman ML, Van Allen EM, Hide W, Hiller E, Rainville I, Ghobrial IM. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood 127(21):2598-606, 2016. e-Pub 2016. PMID: 26903547.
- Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, Calcinotto A, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, Roccaro AM, Ghobrial IM. Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia 30(5):1103-1115, 2016. e-Pub 2016. PMID: 26859080.
- Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y, Sahin I, Chiarini M, Manier S, Cea M, Aljawai Y, Glavey S, Morgan E, Pan C, Michor F, Cardarelli P, Kuhne M, Ghobrial IM. CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep 12(4):622-635, 2015. e-Pub 2015. PMID: 26190113.
- Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, Varga C, Mitsiades CS, Paba-Prada C, Schlossman R, Munshi N, Anderson KC, Richardson PP, Weller E, Ghobrial IM. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol 169(6):851-858, 2015. e-Pub 2015. PMID: 25833301.
- Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y, Asara JM, Roccaro AM, Kimmelman AC, Ghobrial IM. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res 75(10):2071-2082, 2015. e-Pub 2015. PMID: 25769724.
- Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, Roccaro AM, Laubach J, Castillo JJ, Paba-Prada C, Treon S, Redd R, Weller E, Ghobrial IM. Extramedullary Waldenström macroglobulinemia. Am J Hematol 90(2):100-104, 2015. e-Pub 2015. PMID: 25349134.
- Reagan MR, Mishima Y, Glavey SV, Zhang Y, Manier S, Lu ZN, Memarzadeh M, Zhang Y, Sacco A, Aljawai Y, Shi J, Tai YT, Ready JE, Kaplan DL, Roccaro AM, Ghobrial IM. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood 124(22):3250-3259, 2014. e-Pub 2014. PMID: 25205118.
- Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang Y, Zhang W, Mishima Y, Ring JE, Tam WF, Xu Q, Maiso P, Reagan M, Sahin I, Sacco A, Manier S, Aljawai Y, Glavey S, Munshi NC, Anderson KC, Pachter J, Roccaro AM, Ghobrial IM. Pyk2 promotes tumor progression in multiple myeloma. Blood 124(17):2675-2686, 2014. e-Pub 2014. PMID: 25217697.
- Roccaro AM, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, Aljawai Y, Sahin I, Kuhne M, Cardarelli P, Cohen L, San Miguel JF, Garcia-Sanz R, Ghobrial IM. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood 123(26):4120-4131, 2014. e-Pub 2014. PMID: 24711662.
- Aljawai Y, Richards MH, Seaton MS, Narasipura SD, Al-Harthi L. β-Catenin/TCF-4 signaling regulates susceptibility of macrophages and resistance of monocytes to HIV-1 productive infection. Curr HIV Res 12(3):164-173, 2014. e-Pub 2014. PMID: 24862328.
Abstracts
- Aljawai YM, Portia Smallbone, Amin M. Alousi, Qaiser Bashir, George L. Chen, Warren B. Fingrut, Hosing CM, Kebriaei P, Marin D, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Impact of Donor Age and Donor-Recipient Sex Mismatch on Hematopoietic Cell Transplantation Outcomes. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
- Hosing CM, Saliba RM, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Bazinet A, Garcia-Manero G, Champlin RE, Andersson BS, Shpall EJ, Popat UR. Allogeneic Stem Cell Transplant with Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Conditioning Regimen in Older Patients with High Risk MDS. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
- Sami SS, Bashir Q, Saini NY, Aljawai YM, Hosing CM, Popat UR, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srour SA. Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
- Popat UR, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Allogeneic Stem Cell Transplantation in Very High-Risk AML/MDS: A Phase 2 Trial. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
- Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Siddiqui UR, Khan HN, Haider AA, Ramdial JL, Nieto Y, Tang G, Lakhani K, Aljawai YM, Kebriaei P, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Daratumumab-Based Second Line Therapy Improves Outcomes after VRD Induction, Upfront Autologous Transplant and Lenalidomide Maintenance. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
- Deen AF, Bashir Q, Saini NY, Aljawai YM, Hosing CM, Popat UR, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis. ASTCT Tandem Meeting 31(2):Supplement, 2025. e-Pub 2025.
- Smallbone P, Cao K, Saliba RM, Alvarez M, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Ramdial JL, Champlin RE, Shpall EJ, Oran B. HLA-DBP1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
- Popat UR, Alousi AM, Bassett RL, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Shigle TL, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
- Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Saeed A, Haider AA, Ramdial JL, Nieto Y, Tang G, Aljawai YM, Kebriaei P, Lee HC, Patel KK, Becnel MR, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Patients with IgD Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
- Cervoni-Curet FN, Milton DR, Garcia R, Hunter L, Ledesma C, Martinez CS, Rondon G, Carmazzi Y, Cao K, Al-Atrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Smallbone P, Saini NY, Srour SA, Champlin RE, Flowers C, Shpall EJ, Fingrut WB. Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide (PTCy)-Based Graft-Versus-Host Disease Prophylaxis. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
- Saliba RM, Aljawai YM, Alousi AM, Oran B, Popat U, Champlin RE, Shpall EJ. Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide. ASH Annual Meeting, 2024. e-Pub 2024.
- Smallbone P, Cao K, Saliba RM, Alvarez M, Fingrut WB, Aljawai Y, Olson AL, Alousi AM, Chen G, Ramdial J, Champlin RE, Shpall EJ, Oran B. HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide. ASH Annual Meeting, 2024. e-Pub 2024.
- Popat U, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen G, Fingrut WB, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial J, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial. ASH Annual Meeting, 2024. e-Pub 2024.
- Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Patel A, Khan HN, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai YM, Ahmed S, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant. ASH Annual Meeting, 2024. e-Pub 2024.
- Sami SS, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srour SA. Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis. ASH Annual Meeting, 2024. e-Pub 2024.
- Deen AF, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis. ASH Annual Meeting, 2024. e-Pub 2024.
- Kawedia JD, Liu X, Sui D, Gulbis AM, Ramdial J, Srour SA, Popat UR, Nieto Y, Kebriaei P, Saini NY, Lin P, Aljawai Y, Pasvolsky O, Lee HC, Orlowski RZ, Thomas SK, Patel KK, Knape C, Delgado R, Champlin RE, Shpall EJ, Qazilbash MH, Thall P, Bashir Q. Lower PG-Free Mel (Evomela) Clearance and Higher Exposure Are Associated with Better Treatment Response in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. ASTCT Annual Conference 30(2, Supplement):S96, 2024. e-Pub 2024.
- Pasvolsky O, Wang Z, Milton DR, Khan HN, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Aljawai Y, Ansari A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Long-Term Responders after Upfront Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma. ASTCT Annual Conference 30(2, Supplement):S379-S380, 2024. e-Pub 2024.
Letters to the Editor
- Marcoux, C, Pasyar, S, Milton, D, Khan, HN, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Neupane, N, Lee, HC, Patel, K, Tang, G, Aljawai, YM, Kebriaei, P, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Pasvolsky, O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. British Journal of Haematology 206: 763-765, 2025.
Selected Presentations & Talks
Local Presentations
- 2022. Allogeneic blood or marrow transplantation (alloBMT) using haploidentical grandchildren donors and post-transplant cyclophosphamide (PTCy) -based GVHD prophylaxis. Conference. Allogeneic blood or marrow transplantation (alloBMT) using haploidentical grandchildren donors and post-transplant cyclophosphamide (PTCy) -based GVHD prophylaxis. Baltimore, MD, US.
- 2022. Transfusion Burden in Older Patients with Hematological Malignancies Undergoing Allogeneic hematopoietic stem cell transplants. Invited. Sidney Kimmel Comprehensive Cancer Center. Baltimore, MD, US.
- 2022. Monitoring of Childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Invited. Division of Medical Oncology Journal Club. Baltimore, MD, US.
Regional Presentations
- 2022. Stem Cell Transplant – Choosing Donors for Older Patients. Invited. Stem Cell Transplantation and Cellular Therapy Department. Houston, TX, US.
- 2022. Allogeneic Transplantation using Haploidentical Grandchildren Donors. Invited. Stem Cell Transplant and Cellular Therapy/ Hematology Oncology Department. Charlottesville, VA, US.
- 2022. Transplanting Older Patients. Invited. Hematology and Oncology Department. Houston, TX, US.
National Presentations
- 2025. Impact of Donor Age and Donor-Recipient Sex Mismatch on Hematopoietic Cell Transplantation Outcomes. Poster. ASTCT Tandem Meetings. Honolulu, Hawaii, US.
- 2023. Pre-Transplant Recipient Clonal Hematopoiesis (CH) Predicts Poor Outcomes in Older Patients Undergoing Allogeneic Blood or Marrow Transplantation (alloBMT). Poster. Pre-Transplant Recipient Clonal Hematopoiesis (CH) Predicts Poor Outcomes in Older Patients Undergoing Allogeneic Blood or Marrow Transplantation (alloBMT). Orlando, FL, US.
- 2022. Allogeneic Blood or Marrow Transplantation (alloBMT) Using Haploidentical Grandchildren Donors and Post-Transplant Cyclophosphamide (PTCy) – Based GVHD Prophylaxis. Poster. Allogeneic Blood or Marrow Transplantation (alloBMT) Using Haploidentical Grandchildren Donors and Post-Transplant Cyclophosphamide (PTCy) – Based GVHD Prophylaxis. New Orleans, LA, US.
- 2013. Lin28B/Let-7 axis regulates Multiple Myeloma proliferation by enhancing c-Myc and Ras survival pathways. Poster. Lin28B/Let-7 axis regulates Multiple Myeloma proliferation by enhancing c-Myc and Ras survival pathways. New Orleans, LA, US.
- 2013. Metabolomic profiling identifies mechanisms regulating hypoxia-induced drug resistance in Multiple Myeloma. Poster. Metabolomic profiling identifies mechanisms regulating hypoxia-induced drug resistance in Multiple Myeloma. New Orleans, LA, US.
- 2013. Bone marrow mobilization of endothelial progenitor cells represents an early pathogenic event during Multiple Myeloma progression. Poster. Bone marrow mobilization of endothelial progenitor cells represents an early pathogenic event during Multiple Myeloma progression. New Orleans, LA, US.
- 2013. Molecular analysis of circulating tumor cells identifies mutations that are distinct from those present in the bone marrow of patients with Multiple Myeloma. Poster. Molecular analysis of circulating tumor cells identifies mutations that are distinct from those present in the bone marrow of patients with Multiple Myeloma. New Orleans, LA, US.
- 2013. MiRNA expression profiling and proteomic analysis of circulating exosomes from Multiple Myeloma patients. Poster. MiRNA expression profiling and proteomic analysis of circulating exosomes from Multiple Myeloma patients. New Orleans, LA, US.
- 2013. Proline-rich tyrosine kinase (Pyk2) promotes tumor progression in Multiple Myeloma through modulation of Wnt/β-catenin signaling pathway. Poster. Proline-rich tyrosine kinase (Pyk2) promotes tumor progression in Multiple Myeloma through modulation of Wnt/β-catenin signaling pathway. New Orleans, LA, US.
- 2013. MicroRNA-dependent modulation of osteogenesis in a 3D in vitro bone marrow model system of Multiple Myeloma. Poster. MicroRNA-dependent modulation of osteogenesis in a 3D in vitro bone marrow model system of Multiple Myeloma. New Orleans, LA, US.
- 2013. A case-control epidemiological study of Waldenström Macroglobulinemia. Poster. A case-control epidemiological study of Waldenström Macroglobulinemia. New Orleans, LA, US.
- 2013. Extramedullary disease in Waldenström Macroglobulinemia. Poster. Extramedullary disease in Waldenström Macroglobulinemia. New Orleans, LA, US.
- 2012. CXCR4 monoclonal antibody, BMS-936564 (MDX-1338), modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma cells. Poster. CXCR4 monoclonal antibody, BMS-936564 (MDX-1338), modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma cells. Atlanta, GA, US.
- 2012. Metabolomic profiling identifies mechanisms regulating hypoxia induced drug resistance in Multiple Myeloma. Poster. Metabolomic profiling identifies mechanisms regulating hypoxia induced drug resistance in Multiple Myeloma. Atlanta, GA, US.
- 2012. Let-7 microRNA family members regulate cell proliferation in Multiple Myeloma. Poster. Let-7 microRNA family members regulate cell proliferation in Multiple Myeloma. Atlanta, GA, US.
- 2012. In vivo targeting of stromal-derived factor-1 as a strategy to prevent myeloma cell dissemination to distant bone marrow niches. Poster. In vivo targeting of stromal-derived factor-1 as a strategy to prevent myeloma cell dissemination to distant bone marrow niches. Atlanta, GA, US.
- 2012. Comparative miRNA expression profiling of circulating exosomes from MGUS and Smoldering Multiple Myeloma patients. Poster. Comparative miRNA expression profiling of circulating exosomes from MGUS and Smoldering Multiple Myeloma patients. Atlanta, GA, US.
- 2010. A downstream effector of the Wnt/beta-catenin signaling pathway, TCF-4, relieves restricted productive HIV replication in monocytes. Conference. A downstream effector of the Wnt/beta-catenin signaling pathway, TCF-4, relieves restricted productive HIV replication in monocytes. Boston, MA, US.
- 2010. 17beta-estradiol inhibits HIV replication in PBMC and induces beta-catenin, a repressor of HIV. Conference. 17beta-estradiol inhibits HIV replication in PBMC and induces beta-catenin, a repressor of HIV. Boston, MA, US.
- 2010. Beta-catenin regulates susceptibility of productive HIV infection in monocytes, monocyte-derived macrophages and astrocytes relevance to NeuroAIDS. Conference. Beta-catenin regulates susceptibility of productive HIV infection in monocytes, monocyte-derived macrophages and astrocytes relevance to NeuroAIDS. Santa Fe, NM, US.
- 2009. HIV-1 Tat antagonizes Wnt/beta-catenin-induced suppression of HIV replication in the central nervous system. Conference. HIV-1 Tat antagonizes Wnt/beta-catenin-induced suppression of HIV replication in the central nervous system. Miami Beach, FL, US.
- 2009. Beta-catenin regulates susceptibility of productive HIV replication between monocytes and monocyte-derived macrophages. Invited. The Forum for Research and Clinical Investigation. Chicago, IL, US.
- 2008. Beta-catenin regulates susceptibility of productive HIV replication between monocytes and monocyte-derived macrophages. Conference. Beta-catenin regulates susceptibility of productive HIV replication between monocytes and monocyte-derived macrophages. Chicago, IL, US.
International Presentations
- 2025. Comparative Outcomes of HCT with Post-Transplant Cyclophosphamide in Older Adults: The Impact of Donor Type. Poster. EHA. Milan, IT.
- 2025. Haploidentical vs Mismatched Unrelated Donor HCT with Post-Transplant Cyclophosphamide Prophylaxis: Donor Age Matters more than Donor Type. Poster. 51st Annual Meeting of the EBMT. Florence, IT.
- 2014. A novel activating somatic mutation of CXCR4 plays a crucial role in modulating Waldenström Macroglobulinemia biology. Conference. A novel activating somatic mutation of CXCR4 plays a crucial role in modulating Waldenström Macroglobulinemia biology, IT.
- 2013. Metabolomic profiling identifies mechanisms regulating hypoxia-induced drug resistance in Multiple Myeloma. Conference. Metabolomic profiling identifies mechanisms regulating hypoxia-induced drug resistance in Multiple Myeloma, SE.
Formal Peers
- 2022. Monoclonal Gammopathy of Renal Significance, diagnosis and management. Baltimore, MD, US.
- 2022. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma risk stratification and management. Baltimore, MD, US.
Grant & Contract Support
| Date: | 2024 - Present |
| Title: | Minimal Residual Disease Guided Maintenance Therapy with Belantamab and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma |
| Funding Source: | GlaxoSmithKline |
| Role: | Co-PI |
| ID: | 2021-0201 |
| Date: | 2021 - 2023 |
| Title: | Training Program in Hematology, Director: Robert Brodsky, MD |
| Funding Source: | NIH/NHLBI |
| Role: | PI |
| ID: | T32 HL007525 |
Patient Reviews
CV information above last modified June 27, 2025